Acrivastine (Cat No.:I013652) is a short-acting histamine 1 receptor antagonist used in the study of allergic rhinitis. It is suitable for the treatment of allergic rhinitis, hay fever, urticaria, eczema, skin pruritus, etc.
| Catalog Number | I013652 |
| CAS Number | 87848-99-5 |
| Molecular Formula | C₂₂H₂₄N₂O₂ |
| Purity | 95% |
| Target | Histamine Receptor |
| Solubility | DMSO: 10.45 mg/mL (Need ultrasonic) |
| Storage | 2-8°C |
| IUPAC Name | (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid |
| InChI | InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ |
| InChIKey | PWACSDKDOHSSQD-IUTFFREVSA-N |
| SMILES | CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O |
| Reference | [1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40.<br>[2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4. |
